Scientific article on Episealer® Knee with up to 10 years’ follow-up published
Episurf Medical (Nasdaq: EPIS B) today announces that a scientific article including long term clinical results from follow-up of patients who received an Episealer® Knee implant for treatment of chondral or osteochondral defects in the knee, has been published in Journal of ISAKOS. The publication, with the title “Satisfactory survivorship and clinical outcomes up to 10 years after the implantation of a novel personalized metal implant for the treatment of osteochondral lesions of the knee”, by Francesca de Caro et al., presents the clinical outcome and implant survival rate for 34 consecutively recruited patients treated by Prof. Peter Verdonk at AZ Monica, Antwerp, Belgium.
The authors conclude that treatment with an Episealer® Knee implant demonstrates encouraging mid-to-long term results with a high survival rate and maintained clinical improvements at up to 10 years’ of follow-up. The publication, which is the first Episealer® publication with 10 years’ clinical results, shows an implant survival rate of 91,2 % at the latest follow-up, and significant improvement in the patient reported outcome measures KOOS at 2 years, and that the results remained stable at the last follow-up.
“This publication highlights how knee cartilage lesions, that can contribute to the development of early osteoarthritis, can be satisfactory treated with the Episealer® Knee implant, and give a sustained clinical outcome. The mean age at surgery was in this study 49.7 years, which shows that the Episealer® Knee works well for the so-called gap patients, that are often considered too old or with too severe damage for biological cartilage repair, while the patients are too young or have too mild damage for full joint replacement. There is a need for treatments that alleviate pain and improve the joint function for this challenging-to-treat group of people, and that is where the Episealer® Knee fits it. We are delighted to see that this study confirms what we have seen so far in other studies, but now over an even longer period of time”, says Katarina Flodström, CEO, Episurf Medical.
For more information, please contact:
Katarina Flodström, CEO, Episurf Medical
Tel: +46 707 38 35 70
Email: [email protected]
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
The information was submitted for publication, through the agency of the above contact person, at 08:45 CEST on October 17, 2025.